Abstract:G protein-coupled receptor 120 (GPR120) is a Gαq coupled GPCR specifically activated by long-chain fatty acids (LCFAs). Functionally, it has been identified as a member of a family of lipid-binding free fatty acid receptors including GPR40, GPR41, and GPR43. Upon stimulation by LCFAs, GPR120 can directly or indirectly modulate hormone secretion from the gastrointestinal tract and pancreas, and regulate lipid and/or glucose metabolism in adipose, liver, and muscle tissues. Additionally, GPR120 is postulated to mediate anti-inflammatory and insulin-sensitizing effects in adipose and macrophages. These benefits suggest that GPR120 agonists have the potential to be an effective treatment for obesity, type 2 diabetes mellitus (T2DM), and other metabolic syndromes.This article highlights and reviews research advances in this field that have been published in patent literature and peer-reviewed journals since 2014.Current development has been hindered by species differences in GPR120 distribution, differences in GPR120-mediated signaling in distinct tissue types, and lack of available ligands with suitable selectivity for GPR120 over GPR40 in both human and rodents. The discovery of β-arrestin biased GPR120 agonists will help elucidate the potential of selective therapeutics that may discriminate between desirable and undesirable pharmacological effects.ALA: α-linolenic acid; AUC: area under the curve; BRET: bioluminescence resonance energy transfer; CCK: cholecystokinin; CHO-K1 cell: Chinese hamster ovary-K1 cell; db/db mouse: diabetic mouse; DHA: docosahexaenoic acid; DIO: diet-induced obesity; DMSO: dimethyl sulfoxide; DPP-4: dipeptidyl peptidase 4; EPA: eicosapentaenoic acid; FA(s): fatty acid(s); FFA(s): free fatty acid(s); FFAR: free fatty acid receptor; FLIPR: fluorescent imaging plate reader; GIR: glucose infusion rate; GLP-1: glucagon-like peptide 1; GP(C)R: G protein-coupled receptor; GSIS: glucose-stimulated insulin secretion; HEK293 cell: human embryonic kidney 293 cell; HOMA-IR: homeostatic measurement assessment of insulin resistance; IP1: inositol phosphate turnover; IPGTT: intraperitoneal glucose tolerance test; LCFA(s): long-chain fatty acid(s); MEDmax: maximal efficacy; MIN6 cell: mouse insulin-secreting cell; NPY: neuropeptide Y; OGTT: oral glucose tolerance test; pERK: phosphorylated ERK; PPAR: peroxisome proliferator-activated receptor; QD: once daily; SAR: structure–activity relationship; siRNA: small interfering ribonucleic acid; STC-1: intestinal secretin tumor cell; T2DM: type 2 diabetes mellitus; U2OS cell: human bone osteosarcoma epithelial cell; uHTS: ultrahigh-throughput screening; ZDF: zucker diabetic fatty.

GPR40-a potential target for diebete mellitus

Physiology and therapeutics of the free fatty acid receptor GPR40.

GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus: the Biological Characteristics and the Chemical Space

Selective Small-Molecule Agonists of G Protein–Coupled Receptor 40 Promote Glucose-Dependent Insulin Secretion and Reduce Blood Glucose in Mice

Role of GPR40 in Pathogenesis and Treatment of Alzheimer's Disease and Type 2 Diabetic Dementia

Differential requirements of arrestin-3 and clathrin for ligand-dependent and -independent internalization of human G protein-coupled receptor 40

Recent advances in the study of G protein-coupled receptor 40/free fatty acid receptor 1

GPR120 agonists for the treatment of diabetes: a patent review (2014 present)

Synthesis and biological evaluation of GPR40/FFAR1 agonists containing 3,5-dimethylisoxazole.

Yhhu4488, a novel GPR40 agonist, promotes GLP-1 secretion and exerts anti-diabetic effect in rodent models

Lipid receptors and islet function: therapeutic implications?

G protein-coupled receptors: signalling and regulation by lipid agonists for improved glucose homoeostasis

Fatty acid receptors as new therapeutic targets for diabetes

Design, Synthesis, and Biological Evaluations of Phenylpropiolic Acid Derivatives As Novel GPR40 Agonists

Advances in Small-Molecule GPR40 Agonists for Treatment of Type 2 Diabetes Mellitus

Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR40 Agonists

Optimization of GPR40 Agonists for Type 2 Diabetes.

Discovery of Novel Potent GPR40 Agonists Containing Imidazo[1,2-A]pyridine Core As Antidiabetic Agents.

Amg 837: A Novel Gpr40/Ffa1 Agonist That Enhances Insulin Secretion And Lowers Glucose Levels In Rodents

G protein-coupled receptors as new therapeutic targets for type 2 diabetes

GPR40 mediates the effects of FFAs on glucose stimulated insulin secretion and the change of intracellular calcium concentration in pancreatic β cells